Bracco Imaging is pointing to favorable results from a clinical trial involving its ProHance MR contrast agent.
In the TRUTH study, published online October 9 in the American Journal of Neuroradiology, a multi-institutional research team led by Dr. Kenneth Maravilla of the University of Washington found that ProHance yielded information similar to Bayer HealthCare Pharmaceuticals' Gadovist agent (known as Gadavist in the U.S.) at the same routine dose of 0.1 mmol/kg of body weight.
The randomized controlled clinical trial included 198 patients who had received the same dose of both agents during two subsequent MRI exams. The studies were read by three blinded readers, who evaluated the images both qualitatively and quantitatively for detecting lesions and accurately characterizing histologically confirmed brain tumors.
The twofold higher concentration of gadolinium in Gadovist/Gadavist offered no benefit over ProHance for routine morphologic imaging of brain tumors, the authors concluded.
